Last reviewed · How we verify
NCT06207929: WAVE
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
trial in Influenza, Human in 18,157 participants. Completed in 7 August 2024.
7 August 2024
Quick facts
| Lead sponsor | Evidation Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 18,157 |
| Start date | 21 January 2024 |
| Primary completion | 7 August 2024 |
| Estimated completion | 7 August 2024 |
| Sites | 1 location across United States |
Conditions studied
- Influenza, Human — all drugs for Influenza, Human →
- COVID-19 — all drugs for COVID-19 →
- Influenza A — all drugs for Influenza A →
- Influenza B — all drugs for Influenza B →
Sponsor
Evidation Health
Who can join
18 and older, any sex, with Influenza, Human or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this decentralized, observational study is to enroll and observe adults in the contingent United States during the 2023-2024 flu season. The main study objectives are to create a dataset of paired wearable data, self-reported symptoms, and respiratory viral infection (RVI) from PCR testing during the 2023-2024 flu season and to develop algorithm that is able to accurately classify asymptomatic and symptomatic RVI and understand the algorithm's performance metrics.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06207929
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Influenza, Human
Currently open trials in the same condition.
- NCT07204964 — A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above · Phase 2 · active not recruiting
- NCT07121192 — A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older · Phase 2 · active not recruiting
- NCT05921448 — Vaccine Pandemic Preparedness Through Airway Immunology Characterization · EARLY_PHASE1 · active not recruiting
- NCT06573008 — Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications · Phase 3 · recruiting
- NCT06622590 — Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine · Phase 1 · active not recruiting
Other Evidation Health trials
Trials by the same sponsor.
- NCT06229444 — Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Pr · NA · completed
- NCT04623138 — A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections · completed
- NCT04584645 — A Digital Flu Intervention for People With Cardiovascular Conditions · NA · completed
- NCT04245800 — Home Testing of Respiratory Illness · completed
- NCT03870997 — Influenza Vaccination Digital Interventions for People Living With Diabetes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06207929 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Evidation Health
- Last refreshed: 5 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06207929.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing